Predictive Oncology subsidiary Helomics and UPMC announced a collaborative agreement to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
